Genomics England Clinical Interpretation Partnership (GeCIP) Board

The Genomics England Clinical Interpretation Partnership (GeCIP) consists of 42 groups or ‘domains’, overseen by the GeCIP Board.
Each domain covers a different disease or topic in the project. The groups are responsible for interpreting the data to improve clinical care, and also undertake complementary research, including medical, computational and social research.

The GeCIP Board oversees the operation of GeCIP and includes representatives from GeCIP funders and the GeCIP domains. Up to three places on the GeCIP Board are reserved for the representatives of the Participant Panel and they contribute and vote as any other member of the GeCIP Board. The individual Participant Panel representatives are free to rotate attendance at the GeCIP Board according to their availability.

Professor Dame Kay Davies is the Dr Lee’s Professor of Anatomy and Associate Head, Development, Impact and Equality, Medical Sciences Division, University of Oxford. Her research interests cover the molecular analysis of neuromuscular and neurological disease, particular Duchenne muscular dystrophy (DMD). She has an active interest in the ethical implications of genetics research and the public understanding of science.

She has considerable experience of biotechnology companies as a conduit for translating the results of experimental science into new therapeutics and diagnostics. She is a founding editor of “Human Molecular Genetics” and a founding fellow of the UK Academy of Medical Sciences. She is a Fellow of the Royal Society and a Member of the European Molecular Biology Organization (HUGO). She has been a Governor of the Wellcome Trust since 2008 and became Deputy Chairman in October 2013. She was made Dame Commander of the British Empire for services to science in 2008.

Professor Sue Hill OBE PhD DSc CBiol FSB Hon FRCP Hon FRCPath is the Chief Scientific Officer for England and the head of profession for the 50,000 healthcare science workforce in the NHS and associated bodies – embracing more than 50 separate scientific specialisms. She is a respiratory scientist by background with an international academic and clinical research reputation.
Professor Hill has a broad portfolio of policy responsibilities across NHS England and the wider NHS and provides professional leadership and expert clinical advice across the whole health and care system. In particular, Sue is the Senior Responsible Officer for Genomics in NHS England has established NHS Genomic Medicine Centres and is now leading the NHS England Personalised Medicine strategy.
A significant part of her role involves working across government, with the Department of Health & Social Care, with the NHS, Public Health and Health Education England and other external stakeholders to inform policy, influence legislation, deliver strategic change and to introduce new and innovative ways of working.

Michael Parker is Professor of Bioethics and Director of the Ethox Centre at the University of Oxford. His main research interest is in the ethics of collaborative global health research. Together with partners at the Wellcome Trust Major Overseas Programmes (MOPs) in Vietnam, Malawi, Thailand, Laos, Kenya, and South Africa he co-ordinates the Global Health Bioethics Network, which is a programme to encourage and promote ethical reflection, carry out ethics research, and build ethics capacity across the MOPs. Michael also leads the ethics programme of the Malaria Genomic Epidemiology Network (MalariaGEN), which carries out genomic research into severe malaria in childhood at 24 sites in 21 countries.

Michael’s other main research interest is in the ethical aspects of the clinical use of genetics. Since 2001, with Anneke Lucassen, Tara Clancy, and Angus Clarke he has co-ordinated the Genethics Club, a national ethics forum for health professionals and genetics laboratory staff in the United Kingdom to discuss the ethical issues arising in their day-to-day practice and to share good practice. This work has been published as Ethical Problems and Genetics Practice (Cambridge University Press, 2012).

Michael is Head of Genetics and Molecular Science at the Wellcome Trust. Having obtained a PhD in biochemistry at the University of Cambridge, he went on to work on the genetics of type 1 diabetes at the Wellcome Trust Centre for Human Genetics in Oxford and the Cambridge Institute for Medical Research.

Michael joined the Wellcome Trust in 2000. His previous role was to manage and develop its scientific portfolio and community of investigators to enable the Trust to achieve its mission. Michael also led development of the Trust’s Strategic Challenge of ‘Maximising the Health Benefits of Genetics and Genomics’.

Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and translational clinical research. In 2007, 2009 and 2011 his research has been independently rated amongst the top ten scientific discoveries in his field. In 2009 he won the Lily Prize of the British Pharmacology Society.

Since 2008 he directs the Barts National Institute of Health Research Cardiovascular Biomedical Research Unit. He was appointed Director of William Harvey Research Institute in 2002 and was elected to the Academy of Medical Sciences in 2008 and was President of the British Hypertension Society (2009-2011). He is an NHS consultant in the Barts Blood Pressure Clinic within the Barts/William Harvey European Society of Hypertension Centre of Excellence. He raised £25m toward the William Harvey Heart Centre which created a translational clinical research centre and was the academic leader that created the Barts Heart Centre bringing 3 hospitals together at Barts in 2015 to create the UK’s largest heart centre (includes UCLH Heart Hospital, the London Chest Hospital and Barts).

He served on the 2011 NICE Guideline Group for hypertension and leads the Joint UK Societies’ Working Group and Consensus on Renal Denervation. In 2014 he became one of the top 200 most highly cited researchers in the world in genomics according to Thomson Reuters.

In 2013 he was appointed Chief Scientist for Genomics England, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection As chief scientist Mark leads on all scientific activities for Genomics England. He engages with NHS scientific teams and the general public to promote, explain and enthuse about the 100,000 Genomes Project. Mark also oversees the Clinical Interpretation Partnership.

Nathan completed his PhD in 1998 at the MRC Clinical Sciences Centre (London), studying gene regulation and fat/cholesterol transport and metabolism. After a number of years as a post-doctoral researcher Nathan joined MRC Head Office in 2004.

After working in a number of scientific areas, in 2009 he took over as Head of Molecular and Cellular Medicine. Responsibilities include managing MRC’s investments and strategy development across a broad area of biomedical research, including mechanisms or technology relevant to understanding aetiology of, or developing treatments for, multiple human diseases or conditions.

Through the Molecular and Cellular Medicine Board, Nathan is responsible for many of MRC’s major Institute and Unit strategic investments and contributing to the development and delivery of MRC strategy.